Alzheimer’s Disease and Dementia

Leading scientific and operational support to plan, execute, and interpret AD clinical trials.

Alzheimer’s disease (AD) and other dementias have devastating healthcare, social, and economic impacts.

An estimated 50 million people worldwide are currently living with dementia, a figure that will almost triple by 2050, making the unmet need for new AD therapies greater than ever.

Cogstate’s data quality programs and digital cognitive assessments are designed to help your research team enhance signal detection via improved measurement and trial design, and expert study conduct, enabling you to make important AD drug development decisions.

Talk with our team about your study

Improve Strategic Study Design

Choosing appropriate endpoints and designing and powering trials are just two examples of the many make-or-break decisions in the planning phase that impact future trial results. Cogstate has the expertise and extensive data sets to advise your team on vital study considerations, help you answer key drug development questions, and reduce risk and uncertainty.

Leverage Insights from Key Landmark Studies
Cogstate is at the forefront of Alzheimer’s research via participation in several key longitudinal public private partnership (PPP) studies such as secondary prevention trials including A4 and DIAN, as well as registries and natural history studies including AIBL, ADNI, BHR, and the APT Webstudy, many of which offer open data sharing to advance collaborative research.
Gain Study Design Guidance from Cognitive Science Experts
Utilizing open data sets made available through our involvement in PPPs, Cogstate scientists are able to advise study teams on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.
Develop Go/No-Go Decision-Making Frameworks
Leveraging robust Go/No-Go decision-making criteria has the potential to increase the efficiency of AD drug development. While the process of determining an appropriate strategy may be initially time-consuming, it is well worth the efforts. Cogstate can help teams develop these strategies.

Optimize Clinical Outcome Assessment for Enhanced Signal Detection

Cogstate’s team of scientific and operational experts deliver innovative technology, proven operational delivery models and leading scientific support for both digital and conventional clinical outcome assessments in AD trials.

Leverage Sensitive and Reliable Computerized Batteries
Cogstate’s computerized batteries of highly sensitive tests provide rapid and reliable measurement of distinct cognitive domains affected by mild cognitive impairment, pre-clinical AD and mild-to-moderate AD. They are grouped into customizable batteries for a complete and nuanced picture of a subject’s cognitive state. Cogstate tests are culture- and education-neutral and designed for repeated administration with minimal practice or learning effects, making them ideal for use in global clinical trials.
Implement Robust Data Quality Programs for Conventional Assessments
Subjective assessments create the potential for variability in administration and scoring that may compromise the integrity of a study. Cogstate supports all aspects of data quality programs—rater training and certification, subject eligibility review, eCOA deployment, central monitoring—with proven methodologies and leading technologies that drive endpoint reliability.

Extensive Experience with the Assessments Commonly Used in AD Trials

Cogstate supports all aspects of data quality programs and has experience training and monitoring frequently used AD assessments, including…

  • Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
  • Alzheimer’s Disease Cooperative Study Instrumental Activities of Daily Living Inventory (ADCS-ADL)
  • Clinical Dementia Rating Scale (CDR)
  • Clinician’s Interview-Based Impression of Change (CIBIC+)
  • Digit Symbol Substitution Test (DSST)
  • Functional Activities Questionnaire (FAQ)
  • Geriatric Depression Scale (GDS)
  • Mini-Mental State Exam (MMSE)
  • Neuropsychiatric Inventory Questionnaire (NPI)
  • Quality of Life-Alzheimer’s Disease (Qol-AD)
  • Rey Auditory Verbal Learning Test (RAVLT)
  • Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
  • Resource Utilization in Dementia (RUD-Lite)
  • Verbal Fluency
  • And dozens more

Support from Leading AD Experts

Cogstate’s team of scientists is experienced with all aspects of clinical conduct in AD trials. They bring this expertise to your trial and can help you make choices to optimize trial design, execution, and analysis of results.

Paul Maruff, PhD

Paul Maruff, PhD

Chief Innovation Officer

Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods.

Eric Siemers, MD

Eric Siemers, MD

Distinguished Medical Adviser

Dr. Siemers’ experience in clinical trials of neurodegenerative disease spans over 25 years, with a research focus on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases.

Chris Edgar, PhD

Chris Edgar, PhD

Chief Science Officer

Dr. Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the development of new technologies.

Robert McCue, PsyD, MSCP

Robert McCue, PsyD, MSCP

Associate Director, Clinical Science

Robert McCue, PsyD, MSCP is a licensed psychologist with 20 years’ experience in neuropsychology and 10 years’ experience teaching assessment and psychopharmacology courses. He completed a PsyD in clinical psychology at the Nova Southeastern University, an internship at the University of Miami, and a master’s degree in clinical psychopharmacology.

Edward Bartolic, PhD

Edward Bartolic, PhD

Senior Director, Clinical Science

Edward I. Bartolic, PhD, is a clinical neuropsychologist with 20 years experience. He has held various scientific positions with contract research organizations, including Director of CNS Research and Scientific Director for Rater Training Services department at i3 Research and Director of Clinical Assessment Technologies at Worldwide Clinical Trials.

Alzheimer’s Disease Clinical Trial Experience

Studies across all phases
Sites supported
Subjects tested
Raters and administrators trained

Decentralized Clinical Trials

We help bring the trial to the patient

As more clinical trials realize the potential of decentralization, Cogstate digital endpoints are enabling at-home, self-administered assessment and our remote rating services are enabling at-home clinician-administered assessment to drive both enhanced data quality as well as patient enrollment, engagement and retention.


Solutions for Every Stage of Your Study Development

Cogstate’s clinical trial services, coupled with innovative operational approaches, advanced analytics, and scientific consulting, help research teams draw conclusions from study data faster and with more accuracy. Learn how we can support your study:

Scientific Consulting

Computerized Cognitive Assessment

Rater Training

Central Monitoring

Scale Management

Remote / At-home Testing

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch